Remoxy Development Not ‘Unmitigated Disaster,’ CEO Reassures; Hunt Begins For New Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer terminates agreement with Pain Therapeutics after reviewing top-line results of five studies done to address FDA complete response letter; Pain says data supports refiling of NDA for its abuse-deterrent long-acting oxycodone formulation by mid-2015.
You may also be interested in...
Keeping Track: FDA On A Complete Response Spree?
The latest drug development news and highlights from our FDA Performance Tracker.
Never Surrender: Pain Therapeutics Eyes 2016 Remoxy Filing
Pain Therapeutics said it will file the opioid with FDA in the first quarter of 2016, based on clinical trial data conducted by its former partner Pfizer.
Pfizer Gets Abuse-Deterrent Claim on One Pain Drug, Then Drops Development of Another
Pfizer got its first abuse-deterrent claim for its pain therapy Embeda. But it has also ended an agreement to develop another potential abuse-deterrent pain drug.